AQST - Aquestive Therapeutics Pharmanovia ink licensing & supply pact for Libervant buccal film

• Aquestive Therapeutics ( NASDAQ: AQST ) on Wednesday said it had entered into a licensing and supply agreement for its Libervant buccal film with healthcare company Pharmanovia.
• AQST's Libervant is a buccally, or inside of the cheek, administered film formulation of diazepam for the treatment of prolonged or acute, convulsive seizures in all ages.
• The licensing agreement was for the European Union, UK, Switzerland, and Norway, as well as countries in the Middle East and North Africa, AQST said in a statement .
• AQST said as per the deal it would get an undisclosed upfront payment and, if approved, milestone payments, and double-digit royalties on net sales of the diazepam buccal film in the licensed territories.
• AQST will serve as the exclusive sole manufacturer and supplier for the product and Pharmanovia will be responsible for all regulatory and commercialization activities.
• UK based Pharmanovia focuses on delivering branded prescription medicines to patients, prescribers and healthcare providers.
• Aquestive Therapeutics ( AQST ) stock -7% to $1.06 in premarket trading.

For further details see: